Effects of 17α-ethynylestradiol-induced cholestasis on the pharmacokinetics of doxorubicin in rats: reduced biliary excretion and hepatic metabolism of doxorubicin

References

• Ballet F, Vrignaud P, Robert J, et al. (1987). Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver. Cancer Chemother Pharmacol 19:240–5
   PubMed Web of Science ®Google Scholar
• Borst P, Elferink RO. (2002). Mammalian ABC transporters in health and disease. Ann Rev Biochem 71:537–92
   PubMed Web of Science ®Google Scholar
• Chan LM, Lowes S, Hirst BH. (2004). The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25–51
   PubMed Web of Science ®Google Scholar
• Chiou WL. (1978). Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level–time curve. J Pharmacokinet Biopharm 6:539–46
   PubMedGoogle Scholar
• Choi YH, Kim SG, Lee MG. (2006). Dose-independent pharmacokinetics of metformin in rats: hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543–52
   PubMed Web of Science ®Google Scholar
• Choi YH, Lee U, Lee BK, Lee MG. (2010). Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2. Br J Pharmacol 161:815–29
   PubMed Web of Science ®Google Scholar
• Choi JS, Piao YJ, Kang KW. (2011). Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 34:607–13
   PubMed Web of Science ®Google Scholar
• Crocenzi FA, Sanchez Pozzi EJ, Pellegrino JM, et al. (2001). Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets. Hepatology 34:329–39
   PubMed Web of Science ®Google Scholar
• Cui Y, Konig J, Buchholz JK, et al. (1999). Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929–37
   PubMed Web of Science ®Google Scholar
• Czeczuga-Semeniuk E, Solczynski S, Dabrowska M, et al. (2004). The effect of doxorubicin and retinoids on proliferation, necrosis and apoptosis in MCF-7 breast cancer cells. Folia Histochem Cytobiol 42:221–7
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• Denk GU, Soroka CJ, Takeyama Y, et al. (2004). Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 40:585–91
   PubMed Web of Science ®Google Scholar
• Duggleby RG. (1995). Analysis of enzyme progress curves by nonlinear regression. Meth Enzymol 249:61–90
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–717
   PubMed Web of Science ®Google Scholar
• Eloranta ML, Heinonen S, Mononen T, Saarikoski S. (2001). Risk of obstetric cholestasis in sisters of index patients. Clin Genet 60:42–5
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. (1982). Pharmacokinetics. 2nd ed. New York: Marcel Dekker
   Google Scholar
• Hidemura K, Zhao YL, Ito K, et al. (2003). Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2. Antimicrob Agents Chemother 47:1636–42
   PubMed Web of Science ®Google Scholar
• Jin HE, Hong SS, Choi MK, et al. (2009). Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis. Pharm Res 26:549–59
   PubMed Web of Science ®Google Scholar
• Key TJ. (1995). Hormones and cancer in humans. Mutat Res 333:59–67
   PubMed Web of Science ®Google Scholar
• Lee HJ, Lee MG. (1999). Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. Res Commun Mol Pathol Pharmacol 105:87–96
   PubMed Web of Science ®Google Scholar
• Lin HL, Kent UM, Hollenberg PF. (2002). Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J Pharmacol Exp Ther 301:160–7
   PubMed Web of Science ®Google Scholar
• Micheline D, Emmanuel J, Serge E. (2002). Effect of ursodeoxycholic acid on the expression of the hepatocellular bile acid transporters (Ntcp and bsep) in rats with estrogen-induced cholestasis. J Pediatr Gastroenterol Nutr 35:185–91
   PubMed Web of Science ®Google Scholar
• Mottino AD, Cao J, Veggi LM, et al. (2002). Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D-glucuronide-induced cholestasis. Hepatology 35:1409–19
   PubMed Web of Science ®Google Scholar
• Muhlfeld A, Kubitz R, Dransfeld O, et al. (2003). Taurine supplementation induces multidrug resistance protein 2 and bile salt export pump expression in rats and prevents endotoxin-induced cholestasis. Arch Biochem Biophys 413:32–40
   PubMed Web of Science ®Google Scholar
• Okabe M, Unno M, Harigae H, et al. (2005). Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333:754–62
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus C, Meier PJ. (2005). Hepatocellular transporters and cholestasis. J Clin Gastroenterol 39:S103–10
   PubMed Web of Science ®Google Scholar
• Rajkumar L, Guzman RC, Yang J, et al. (2004). Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments. Breast Cancer Res 6:R31–7
   PubMed Web of Science ®Google Scholar
• Rocha AB, Lopes RM, Schwartsmann G. (2001). Natural products in anticancer therpay. Curr Opin Pharmacol 1:364–9
   PubMedGoogle Scholar
• Rodriguez-Garay EA. (2003). Cholestasis: human disease and experimental animal models. Ann Hepatol 2:150–8
   PubMedGoogle Scholar
• Ruiz ML, Villanueva SSM, Luquita MG, et al. (2007). Beneficial effect of spironolatone administration on ethylestradiol-induced cholestasis in the rat: involvement of up-regulation of multidrug resistance-associated protein 2. Drug Metab Dispos 35:2060–6
   PubMed Web of Science ®Google Scholar
• Savander M, Ropponen A, Avela K, et al. (2003). Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. Gut 52:1025–9
   PubMed Web of Science ®Google Scholar
• Scheffer GL, Kool M, Heijn M, et al. (2000). Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 60:5269–77
   PubMed Web of Science ®Google Scholar
• Schwarz EB, Hess R, Trussell J. (2009). Contraception for cancer survivors. J Gen intern Med 24:401–6
   PubMed Web of Science ®Google Scholar
• Sivaraman L, Stephens LC, Markaverich BM, et al. (1998). Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats. Carcinogenesis 19:1573–81
   PubMed Web of Science ®Google Scholar
• Smylie MG, Wong R, Mihalcioiu C, et al. (2007). A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Invest New Drugs 25:155–9
   PubMed Web of Science ®Google Scholar
• Soucek P, Gut I. (1992). Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 22:83–103
   PubMed Web of Science ®Google Scholar
• Speeg KV, Maldonado AL. (1994). Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother Pharmacol 34:133–6
   PubMed Web of Science ®Google Scholar
• Stephens RH, O'Neill CA, Warhurst A, et al. (2001). Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 296:584–91
   PubMed Web of Science ®Google Scholar
• Suzuki T, Zhao YL, Nadai M, et al. (2006). Gender-related differences in expression and function of hepatic P-glycoprotein and multidrug resistance-associated protein (Mrp2) in rats. Life Sci 79:455–61
   PubMed Web of Science ®Google Scholar
• Trauner M, Arrese M, Soroka CJ, et al. (1997). The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 113:255–64
   PubMed Web of Science ®Google Scholar
• Vlaming ML, Mohrmann K, Wagenaar E, et al. (2006). Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319–27
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. (1975). A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–90
   PubMed Web of Science ®Google Scholar
• Yao K, Lee ES, Bentrem DJ, et al. (2000). Antitumor action of physiological estradiol on tamoxifem-simulated breast tumors grown in athymic mice. Clin Cancer Res 6:2028–36
   PubMed Web of Science ®Google Scholar
• Zawaira A, Matimba A, Masimirembwa C. (2008). Prediction of sites under adaptive evolution in cytochrome P450 sequences and their relationship to substrate recognition sites. Pharmacogenet Genomics 18:467–76
   PubMed Web of Science ®Google Scholar
• Zelcer N, Saek T, Reid G, et al. (2001). Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276:46400–7
   PubMed Web of Science ®Google Scholar